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Antihypertensive treatments have been shown to reduce the risk of Alzheimer’s disease
(AD). The renin-angiotensin system (RAS) has been implicated in AD, and thus RAS-acting
AHTs (angiotensin converting enzyme inhibitors (ACEIs), and angiotensin-II receptor block-
ers (ARBs)) may offer differential and additional protective benefits against AD compared
with other AHTs, in addition to hypertension management.
Methods
In a retrospective cohort design, we examined the medical and pharmacy claims of a 20%
sample of Medicare beneficiaries from 2007 to 2013, and compared rates of AD diagnosis
for 1,343,334 users of six different AHT drug treatments, 65 years of age or older
(4,215,338 person-years). We compared AD risk between RAS and non-RAS AHT drug
users, and between ACEI users and ARB users, by sex and race/ethnicity. Models adjusted
for age, socioeconomic status, underlying health, and comorbidities.
Findings
RAS-acting AHTs were slightly more protective against onset of AD than non-RAS-acting
AHTs for males, (male OR = 0.931 (CI: 0.895–0.969)), but not so for females (female OR =
0.985 (CI: 0.963–1.007)). Relative to other AHTs, ARBs were superior to ACEIs for both
men (male ARB OR = 0.834 (CI: 0.788–0.884); male ACEI OR = 0.978 (CI: 0.939–1.019))
and women (female ARB OR = 0.941 (CI: 0.913–0.969); female ACEI OR = 1.022 (CI:
0.997–1.048)), but only in white men and white and black women. No association was
shown for Hispanic men and women.
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Conclusion
Hypertension management treatments that include RAS-acting ARBs may, in addition to
lowering blood pressure, reduce AD risk, particularly for white and black women and white
men. Additional studies and clinical trials that include men and women from different racial
and ethnic groups are needed to confirm these findings. Understanding the potentially bene-
ficial effects of certain RAS-acting AHTs in high-risk populations is of great importance.
Introduction
An estimated 5.5 million Americans have Alzheimer’s disease (AD), which is the most com-
mon cause of dementia [1]. The lack of disease-modifying treatments for AD has focused
attention to commonly prescribed medications for other conditions (i.e., so-called drug repur-
posing or repositioning) that may reduce risk and delay onset of AD, benefitting individuals,
families, and societies [2]. Vascular disease, and in particular hypertension, has long been rec-
ognized as a risk factor for AD and other dementias [3]. Hypertension is highly prevalent
among United States adults (29%), is higher for African Americans than whites (44% com-
pared to 32%), and rises with age for men (64% ages 65–74, and 66.7% ages 75 and older) and
for women (69.3% ages 65–74, and 78.5% ages 75 and older) [4, 5].
Antihypertensive (AHT) medications are commonly prescribed for adults with chronic
high blood pressure, spanning six different widely used therapeutic classes: two renin-angio-
tensin system (RAS) acting classes (angiotensin converting enzyme inhibitors (ACEIs) and
angiotensin-II receptor blockers (ARBs)), and four classes that work primarily via non-RAS
mechanisms (beta blockers (BBLs), calcium channel blockers (CCBs), loop diuretics (LDs),
and thiazide-like diuretics (TDs)). In the US in 2014, among the civilian, non-institutionalized
population age 65 years and over, 24.1% were prescribed ACEIs, 12.2% ARBs, 30.5% BBLs,
17.8% CCBs, and 21.1% diuretics within a single month [6].
There is observational evidence showing that AHT treatments, regardless of drug class, are
protective against cognitive decline and incident dementia [3]. Meta-analyses reviewing evi-
dence from both observational studies and randomized controlled trials (RCTs) have shown
AHT drug treatment may be protective against incident dementia or cognitive decline but
results were inconsistent due to variation across study designs, follow-up periods, patient pop-
ulations, the definition of hypertension status, and outcomes where, in the majority of cases,
cognitive function was a secondary outcome or part of a substudy [3, 7–11]. Some observa-
tional studies suggest that RAS-acting AHTs are more protective against AD than other AHTs
[12]. Human and animal studies suggest that RAS medications may modulate numerous pro-
tective mechanisms against AD (see Kehoe, 2018 for review), independent of blood pressure
effects [13–18]. In a sample of veterans, predominately white males, Li et al (2010) provided
evidence that within RAS-acting AHTS, ARBs were more protective against dementia than
one ACEI (lisinopril) [19]. Other studies, including the randomized controlled trials ONTAR-
GET, TRANSCEND, and PROFESS, have found no effect of ACEIs and ARBs on cognitive
function, but no direct comparisons were made between these RAS-acting classes and non-
RAS acting classes [20, 21]. Several more recent studies showed that individuals taking
RAS-acting antihypertensives exhibited slower disease progression, likely via less AD related
neuropathology, particularly neurofibrillary tangle pathology, than individuals taking non-
RAS-acting antihypertensives [12, 22–25]. It is hypothesized that ARBs are more protective
than ACEIs because of ACEI’s role in amyloid-β degradation (shown in in vitro and in animal
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studies, see Kehoe 2018 for review), but existing RCTs, where AD was the targeted outcome,
are not yet completed [26–28]. Studies of AHT drugs in people with cardiovascular morbidi-
ties have not reported cross-class differences in relation to secondary investigations on cogni-
tion and dementia [3, 7, 8, 12, 19, 29, 30].
Despite important advances in the potential RAS-AD link, and efforts to enroll minorities
in clinical trials, there have been limited population-based investigations on these relationships
in samples with substantial representation of women and racial/ethnic minorities, providing
little evidence on cross-class differences for specific subpopulations that could inform the gen-
eralizability of various treatments on AD risk. Investigations of large datasets can help close
this research gap. It is well documented that RAS-acting agents function differently in African
Americans compared to Caucasians, with higher endogenous sodium and lower renin levels
for African Americans. Because African Americans are at higher risk for AD, and it is
unknown whether there are racial differences in brain RAS function, it is important to address
these mechanistic questions in all ethnic groups. Estrogen also has a role in RAS-mediated
effects on AD pathology, while differences across race in genetic coding for drug-metabolizing
enzymes and transporters suggest that these effects could vary across sex and race/ethnicity
[31, 32]. Some medications for chronic conditions, such as statins, have differential associa-
tions with AD risk across subpopulations, but such relationships have not been similarly exam-
ined for RAS-acting and non-RAS-acting AHTs [33].
To our knowledge, this is the first study to examine AD risk reduction among six different
anti-hypertensive medications including both RAS-acting and non-RAS-acting AHTs in Afri-
can American, Hispanic, and Caucasian men and women. While the different AHTs are simi-
larly effective in reducing blood pressure, differences in their association with AD risk for
black, non-Hispanic white, and white men and women could point to effects independent of
blood pressure and have implications for clinicians, particularly those who serve minority pop-
ulations [34, 35]. We used longitudinal claims data from 2007–2013 for a representative sam-
ple of fee-for-service Medicare beneficiaries ages 67 and older to analyze the association of
RAS-acting AHT use compared to non-RAS-acting AHT use and AD onset. We examined dif-
ferences within RAS-acting AHTs by comparing ACEIs and ARBs, and whether associations
vary by sex and race/ethnicity in multivariable regressions that control for age, sex, race, edu-
cation, income, comorbidities, health care utilization tendencies, and statin use.
Methods
Data
We examined the medical and pharmacy claims of a random 20% sample of Medicare benefi-
ciaries enrolled in traditional Medicare (fee-for-service) from 2007 to 2013. The enrollment file
includes beneficiary characteristics, which can be linked with claims from Medicare Parts A, B,
and D. Part D claims include key elements related to prescription drug events, while Parts A
and B claims capture inpatient and outpatient encounters, including detailed diagnosis and
procedure codes (International Classification of Diseases, Ninth Revision (ICD-9)). These data
were further supplemented with claims histories from the Chronic Conditions Warehouse.
Institutional review board approval was granted by the University of Southern California Uni-
versity Park IRB, which granted a waiver of participant consent under 45 CFR 46.116(d).
Study sample
The study sample consisted of Medicare beneficiaries age 67 and older. We required observa-
tion of each individual for a minimum of three years with consecutive fee-for-service enroll-
ment, Part D enrollment, and no death. Individuals were required to have used at least one
Anti-hypertensive medication classes and Alzheimer’s disease risk
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AHT class for two consecutive years, no prior AD diagnoses, and no prior use of acetylcholin-
esterase inhibitors (AChEIs) or memantine. We required an AD index diagnosis (ICD-9
331.0) to be verified with either a second AD diagnosis code or ‘dementia specified elsewhere’
diagnosis code in a subsequent claim within the study period (2009–2013). The analytic sample
consisted of 1,343,334 unique beneficiaries, followed for a total of 4,215,338 person-years
(2,820,575 for females, 3,501,668 for non-Hispanic whites, 295,521 for blacks, 230,887 for His-
panics, and 187,262 for Asian, Native American, or unknown race/ethnicity). Table 1 shows
the characteristics of the analytic sample.
Measuring AHT exposure
We identified AHT use by selecting Part D claims (2007–2013) for the following classes: angio-
tensin-converting enzyme inhibitors (ACEI), angiotensin-II receptor blockers (ARB), beta-
blockers (BBL), calcium channel blockers (CCB), loop diuretics (LDs), and thiazide-like
diuretics (TDs). We defined an AHT user as any individual with 90 days supply and at least
two drug claims in a year for two consecutive years. This threshold was chosen as the mini-
mum necessary to ensure regular use of the drug during the exposure period, but other defini-
tions were used in sensitivity analyses (see Limitations, below). Combination use of multiple
Table 1. Sample characteristics.
Any AHT RAS no RAS ACEI ARB Other 4
AD (verified) 0.97% 0.88% 1.12% 0.92% 0.81% 0.97%
# of AHT classes used 2.1 2.5 1.5 2.4 2.6 2.3
Combo use rate 69% 84% 42% 83% 87% 79%
Age 78.3 78.0 78.9 77.8 78.2 78.4
Female 67% 66% 69% 62% 72% 68%
White 83% 82% 85% 84% 79% 83%
Black 7% 7% 7% 7% 7% 7%
Hispanic 5% 6% 4% 6% 7% 5%
Other 4% 5% 4% 3% 7% 4%
% HS grad 76% 75% 76% 75% 75% 75%
Median income $54,794 $54,777 $54,826 $53,846 $56,252 $54,577
# physician visits 9.4 9.3 9.5 8.8 10.4 9.5
Comorbidity index 1.34 1.31 1.41 1.31 1.31 1.37
Percent of sample with prior diagnosis of:
AMI 7% 7% 7% 7% 6% 7%
ATF 20% 18% 23% 18% 18% 21%
Diabetes 44% 47% 36% 47% 48% 44%
Stroke 18% 17% 19% 17% 17% 18%
Hyperlipidemia 88% 89% 85% 88% 91% 88%
Non-AD dementia 8% 8% 10% 8% 7% 8%
Person-years 4,215,338 2,727,821 1,487,517 1,764,546 1,034,502 3,708,796
Unique beneficiaries 1,343,334 942,456 615,116 640,715 380,606 1,204,168
Sample characteristics of 2009–2013 Medicare enrollees with use of six classes of antihypertensive (AHT) prescription drugs (two renin-angiotensin (RAS) acting
classes: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs), and four other classes: beta-blockers, calcium channel blockers,
loop diuretics, and thiazide diuretics). Users defined as those with 90 possession days and 2 claims in year t-1 and year t-2. Sample restricted to person-years with 3 years
fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior AD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or
memantine. The comorbidity index is the Hierarchical Condition Category (HCC) risk adjuster.
https://doi.org/10.1371/journal.pone.0206705.t001
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AHTs is relatively common; Fig 1 shows the percent of the study sample using each of the
AHT drug classes in 2013. Participants were classified as RAS-acting AHT users if they were
taking a RAS AHT drug alone, or in combination with another AHT.
Study design
We compared onset of AD for RAS-acting AHT drug users to those using only non-RAS-act-
ing AHTs, using index date of AD diagnosis. Measurement error in the timing of AD diagnosis
does is unlikely to bias our results because the same error exists for the AHT users in both the
exposure and comparator groups. To mitigate concern that imminent AD onset could lead to
poor adherence or discontinuation of AHT use, we designated years t-1 and t-2 as AHT expo-
sure years, prior to assessing AD risk in year t. In addition to analyses that define RAS use as
the aggregate of ACEI and ARB, we also compared the independent effects of ACEI and ARB
use to non-RAS-acting AHT use. Sex and race/ethnicity specific analyses use only members of
the same subgroup as the comparison group, thus estimated differences in association with
type of AHT is attributed to drug class and not due to (unobserved) differences across race/
ethnicity.
Statistical analyses
We examined the association of RAS AHT use (in years t-1 and t-2) and incident AD (year t),
during the years t = 2009 to t = 2013. We used multivariable logistic regression to control for
the potentially confounding roles of age, age squared, sex, race, high school graduation rate
within the beneficiary’s zip code (quartiles), zip code median income (quartiles), statin use,
years since hypertension diagnosis, comorbidity index (quartiles), number of physician visits
(quartiles), and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial
infarction, stroke, and hyperlipidemia. Time-varying covariates were measured in year t-1.
Health status was measured with past diagnosis of key comorbidities, as well as the Centers for
Fig 1. Antihypertensive (AHT) use groups in 2013. 2013 use of AHTs by Medicare enrollees (angiotensin converting enzyme inhibitors (ACEIs),
angiotensin-II receptor blockers (ARBs), beta-blockers (BBL), calcium channel blockers (CCB), loop diuretics, and thiazide diuretics). Users defined as
those with 90 possession days and 2 claims. Sample restricted to 2013 observations with sample restrictions described in Table 1. RAS (renin
angiotensin system) acting drugs are ACEIs and ARBs.
https://doi.org/10.1371/journal.pone.0206705.g001
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Medicaid and Medicare Services-Hierarchical Condition Category (CMS-HCC), an index
based on health status from diagnostic data and demographics, in which higher numbers indi-
cate worse health. The CMS uses this index to predict health expenditures in the next year, and
it correlates highly with mortality [36]. We used years since hypertension diagnosis, as mea-
sured by the Chronic Conditions Warehouse (CCW), to control for unobserved AHT use in
the years prior to Medicare Part D enrollment. Race/ethnicity was determined with the benefi-
ciary race code in CMS enrollment data, and with the application of a name-based identifica-
tion algorithm from the Research Triangle Institute [37]. Sex and race/ethnicity specific
analyses use only members of the same subgroup as the comparator. Standard errors were
clustered at the county level. We ran analyses for the sample as a whole, as well as for each
sex-race/ethnicity subgroup.
Results
Table 1 shows the sample characteristics by type of AHT. The average age of RAS users is
78.0 years, while those using the other four AHTs averaged 78.4 years. RAS users had an aver-
age comorbidity score of 1.31 and averaged 9.3 physician visits per year, compared to 1.37 and
9.5 for users of the other four non-RAS-acting AHTs. Comorbidity prevalence across the two
groups was: acute myocardial infarction (7% for both groups), atrial fibrillation (18% for RAS
users, 21% for other non-RAS-acting AHT users), diabetes (47% for RAS users, 44% for non-
RAS-acting AHT users), stroke (17% for RAS users, 18% for non-RAS-acting AHT users),
hyperlipidemia (89% for RAS users, 88% for non-RAS-acting AHT users), and non-AD
Fig 2. Odds ratios of AD incidence for RAS users relative to non-RAS users, with 95% CIs. Each OR is the result
from a separate logistic regression, which compares RAS AHT users to non-RAS AHT users in the same sex-race/
ethnicity subgroup. Sample of 2009–2013 Medicare enrollees with use of antihypertensive (AHT) prescription drugs
(angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, calcium
channel blockers, loop diuretics, and thiazide diuretics). Sample sizes of person-years are: 4215338 for all, 2820575 for
females, 1394763 for males, 2324640 for white females, 1177028 for white males, 221664 for black females, 73857 for
black males, 154142 for Hispanic females, and 76745 for Hispanic males. Users defined as those with 90 possession
days and 2 claims in year t-1 and year t-2. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D,
age 67+, no deaths in the reference year (year t), no prior AD diagnoses, and no prior use of acetylcholinesterase
inhibitors (AChEIs) or memantine. RAS (renin angiotensin system) acting drugs are ACEIs and ARBs. Controls are
age, age squared, sex, race, education, income quartiles, statin use (t-1), years since hypertension diagnosis, HCC
comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute
myocardial infarction, stroke, and hyperlipidemia. Standard errors are clustered at the county level.
https://doi.org/10.1371/journal.pone.0206705.g002
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dementia (8% for both groups). Clinical guidelines currently recommend both RAS-acting
and non-RAS-acting AHTs as first line therapies for hypertension, in the nonblack hyperten-
sive population, including those with diabetes. Notably, 2017 blood pressure guidelines advise
that initial AHT treatment for African Americans should include a TD or CCB instead of a
RAS-acting AHT [35].
During the years 2009–2013, 0.97% of AHT users were diagnosed with AD each year
(Table 1). RAS-acting AHT users had statistically significantly lower rates of AD incidence
(0.88%), compared to non-RAS-acting AHT users (0.97%). ARB users had a statistically signif-
icantly lower incidence rate (0.81%), compared to ACEI users (0.92%). For comparison, in
Medicare samples without drug use or death restrictions, we find AD incidence rates between
2.0% and 2.7%, depending on how restrictive we are in determining who is at risk. The Alzhei-
mer’s Association estimates that the general population ages 65 and older had an AD incidence
rate of 1.15% in 2013. [38, 39]
The odds ratios (OR) from multivariable logistic regressions of AD risk and RAS-acting
AHT use are depicted in Fig 2, with odds ratios, p-values, and confidence intervals provided in
S1 Table. Each OR is the result from a separate regression, which compares RAS AHT users to
non-RAS AHT users in the same sex-race/ethnicity subgroup. Use of RAS AHTs was associ-
ated with significantly reduced risk of AD for males (OR = 0.931, CI: 0.895–0.969), but not
females (OR = 0.985, CI: 0.963–1.007). The significant association for males was largely driven
by white males (OR = 0.932, CI: 0.892–0.974). Black and Hispanic males, and females of all
races/ethnicities had OR close to 1.0 and no significant association between RAS AHT use and
AD risk. Hispanic males (OR = 0.911, CI: 0.771–1.076) showed no significant association
driven by large confidence intervals.
Results from models that separated RAS AHTs into their component classes (ACEIs and
ARBs) are reported in Fig 3 and S2 Table. Each pair of ORs (for ACEI and ARB) represents
results from a separate regression, which compares ACEI and ARB users to non-RAS users in
the same sex-race/ethnicity subgroup. The use of ACEIs had no significant association with
AD risk, across men and women and all races/ethnicities. By contrast, ARB use showed signifi-
cant protection against AD for white females (OR = 0.933, CI: 0.902–0.964), black females
(OR = 0.912, CI: 0.832–0.998), and white males (OR = 0.825, CI: 0.772–0.882).
Discussion
We analyzed the association between use of RAS-acting AHTs and AD onset across sex and
race/ethnicity, and allowed for the possible separate biological roles of ACEIs and ARBs as has
been suggested for AD [18, 40, 41]. While there is some evidence of risk reduction from RAS-
acting AHTs, most of that association is driven by ARBs rather than ACEI use.
Why RAS AHTs may provide benefit in AD, compared to other AHTs, is potentially driven
by a combination of genetic, pre-clinical, epidemiological, and a limited number of directly
relevant clinical factors [18, 42, 43]. Multiple components of the RAS are associated with
changes to amyloid-beta (Aβ) and tau levels in both pre-clinical models as well as human post-
mortem studies [18, 24, 44–46]. Furthermore, RAS-acting AHTs have been reported to reduce
the incidence of AD and slow the progression from MCI to AD in African Americans and
Caucasians, leading to new studies whereby RAS-acting drugs are being tested as interventions
for AD [12, 18, 19, 40, 41, 47].
Both ARBs and ACEIs were designed to treat hypertension by reducing signaling of the
angiotensin II peptide hormone via the angiotensin II type-1 receptor (AT1R), but they differ
in how they achieve the reduction in angiotensin II, and may differentially affect processes
related to AD [3, 27]. ACEIs inhibit the activity of angiotensin I-converting enzyme (ACE)
Anti-hypertensive medication classes and Alzheimer’s disease risk
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and thus the formation of angiotensin II. ARBs do not directly interfere with angiotensin II
production, but instead block the binding and signaling of angiotensin II via its receptor
AT1R. However, ACE has also been reported to degrade Aβ, and it has therefore been sug-
gested that ACEIs may adversely alter ACE-mediated degradation of Aβ in the brain [27]. This
would likely be disadvantageous, since Aβ is thought to be a significant factor in the develop-
ment and pathology of AD. Yet ARBs could selectively inhibit the detrimental effects of angio-
tensin II without inhibiting ACE.
The potential involvement of the RAS in AD is particularly important in the African Ameri-
can population, because of differences in how the RAS functions in this ethnic group. The
peripheral RAS functions differently between African Americans and Caucasians, with higher
endogenous sodium and lower renin levels for African Americans. It is less clear, however, if
in the brain, RAS functions differently between groups, but data suggest that AD related brain
benefits via RAS therapy are applicable to both groups [12]. Additionally, both AD incidence
and prevalence are higher in African Americans compared to Caucasians [48]. These results
are especially important because the US population aged 65 years and older is projected to
more than double by 2060 [49]. Over the same time period, the African American population
is expected to grow from 14% to 18% of the total population, while the single race non-
Hispanic white population is expected to decrease from 62% to 44% [50]. African Americans
are also more likely to be hypertensive, an independent risk factor for AD, leading to an overall
Fig 3. Odds ratios of AD incidence for ACEI and ARB users, relative to non-RAS users, with 95% Cis. Each pair of
ORs (for ACEI and ARB) represents results from a separate logistic regression, which compares ACEI and ARB users
to non-RAS users in the same sex-race/ethnicity subgroup. Sample is 2009–2013 Medicare enrollees with use of
antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II
receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics). Sample sizes
of person-years are: 4215338 for all, 2820575 for females, 1394763 for males, 2324640 for white females, 1177028 for
white males, 221664 for black females, 73857 for black males, 154142 for Hispanic females, and 76745 for Hispanic
males. Users defined as those with 90 possession days and 2 claims in year t-1 and year t-2. Sample restricted to
person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior AD
diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. RAS (renin angiotensin system)
acting drugs are ACEIs and ARBs. Controls are age, age squared, sex, race, education, income quartiles, statin use (t-1),
years since hypertension diagnosis, HCC comorbidity index, number of physician visits, and indicators for past
diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, stroke, and hyperlipidemia. Standard errors are
clustered at the county level.
https://doi.org/10.1371/journal.pone.0206705.g003
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less healthy population. Thus, understanding the potentially beneficial effects of certain RAS-
acting AHTs in this high-risk population is of great importance.
The results show that RAS AHTs are associated with lower AD risk for males (OR = 0.931,
CI: 0.895–0.969) than females (OR = 0.985, CI: 0.963–1.007). In models that separated ACEIs
and ARBs, the level of risk lowering in the ARBs was greater for males (OR = 0.834, CI: 0.788–
0.884) than females (OR = 0.941, CI: 0.913–0.969). These disparities could relate to interac-
tions that exist between estrogen and the RAS throughout life that may also have a bearing on
late life RAS-mediated changes to AD pathology [32]. It is also possible that the beneficial
effects of RAS-acting AHTs would be more evident in younger and middle aged women who
are nearer the menopausal transition, while RAS related benefits for men may extend across
the lifespan. It is worth noting that RAS-acting antihypertensives are contraindicated during
the second and third trimesters of pregnancy because of increased risk of fetal renal damage,
so women taking RAS therapy would be prescribed different antihypertensives during this
time. It is therefore possible that women who are planning to become pregnant change their
antihypertensive regimen and are likely to stay on non-RAS medications after pregnancy. As
such, the RAS benefits favoring men may reflect longer exposure times from RAS-acting medi-
cations favoring longer brain related protection.
Unlike the other population subgroups, there was no benefit on average of ARBs for His-
panic females (OR = 0.996, CI: 0.911–1.088). It is not clear why there was no benefit in this
population, particularly when there is high prevalence of RAS-associated obesity, metabolic
disorders, and hypertension, all of which are risk factors for AD [51]. Yet, very little is known
regarding whether there are ethnic differences in the RAS in Hispanics, in the same way that
differences exist between Caucasians and African Americans. Unlike Caucasians and African
Americans, there are currently no widely disseminated guidelines for treating hypertension in
Hispanic populations, likely because many clinical studies have not included Hispanic popula-
tions and there is little literature describing RAS function among Hispanics [51–53].
While there is now some evidence of long term effects of midlife hypertension management
on improved late-life cognition, our study focuses on the role of relatively recent hypertension
treatment for older adults [54]. This approach is driven by evidence suggesting that there are
also short term effects of AHT treatment on cognition, especially for ARBs [19, 55]. Of note,
our results showing cognitive preservation are likely the result of multiple RAS-related bene-
fits, in addition to the medications’ direct action on tau and amyloid-β. Mechanisms include
improved or preserved cerebral blood flow, anti-inflammatory effects, and pro-cholinergic
effects [14, 25, 56, 57]. We have also reported that RAS-acting medications, used for only four
months, were able to cross the blood brain barrier and alter ACE activity and levels in the
brain in middle aged individuals with a parental history of AD [58]. This suggests that while
the brain and peripheral RAS operate largely independently, so long as the blood brain barrier
is not compromised, RAS-acting medications are able to change components of the brain RAS
in a relatively short amount of time.
Limitations
The Medicare claims data provide an excellent setting for this type of study, with large and
diverse samples, and no recall bias. There are, however, several limitations to these data,
including the possibility that AHT use and/or AD are measured imprecisely. For example,
switching between classes of AHT within a year would allow someone to be marked as a user
of multiple classes within a year, or have some uncaptured use. This behavior, however, would
lessen the observed differences across classes, and therefore bias our results toward zero. To
address concerns about the effects of AHT use that occurred prior to observation in 2007, we
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control for years since hypertension diagnosis, which is observed as far back as 1999 if contin-
uously enrolled in FFS Medicare. We are also concerned that AD diagnosis practices are
imprecise, which can lead to measurement error in the timing of diagnosis, and across types of
dementias. To address these problems, we require that AD diagnoses are verified on subse-
quent claims. Additionally, this type of measurement error would only be a problem if it varied
systematically across AHT classes, which seems implausible. Another limitation of the claims
data is that we are unable to control for apolipoprotein E (ApoE) status given current clinical
practice does not test for ApoE.
When comparing users of multiple classes of AHTs, it is possible that unobserved patient
characteristics could sort users across classes, and also affect AD risk differences. Few observ-
able differences were found (Table 1) and we include a detailed set of control variables such as,
age, comorbid conditions, zip code level high school graduation rates, and zip-code level
median income in our estimation models. Additionally, all six classes of AHTs have generic
versions available within the years of our study, making them inexpensive for our sample of
Medicare Part D beneficiaries, and therefore diminishing the potential for socioeconomic dif-
ferences to influence drug choices. Ideally, we would be able to control for blood pressure, so
that we could precisely identify the role of AHT classes, net of blood pressure effects. Since we
cannot observe blood pressure, we include controls for comorbidities that serve as proxies for
extreme blood pressure: acute myocardial infarction, atrial fibrillation, and stroke.
Differences in the guidelines for hypertension treatment across ethnic groups might also
cause systematic variation in the characteristics of AHT users across class. However, any such
treatment selection patterns would be held constant in our analyses of population subgroups,
which only compare each sex and race/ethnicity to members of the same group. Additionally,
Table 1 shows the characteristics of the different AHT use groups, and gives empirical evidence
that these groups have similar underlying characteristics, suggesting that protectiveness differ-
ences across class are not driven by patient selection.
The study period investigated here coincided with rapid growth in enrollment in Medicare
Advantage plans. This selective attrition would only potentially influence the results if users of
a particular AHT class were more or less likely to join a Medicare Advantage plan, which is
likely implausible. However, we conducted sensitivity analyses on a sample restricted to sub-
jects that survived and were observed through to the end of 2013 (no movement between fee-
for-service and Medicare Advantage plans). The results of these analyses are featured in S3 and
S4 Tables, and show no meaningful differences from the main results.
As shown in Fig 1, use of combinations of AHTs within a single year is common. For this
reason, differential combination patterns between ACEIs and ARBs could be responsible for
the relatively greater AD protection from ARB use. Fig 1 shows relatively similar combination
use patterns for these two classes, except for TD use that is more common for ARB users than
ACEI users. Ordinarily there are certain considerations, due to drug interactions, of what
types of diuretics can be taken with RAS-acting AHTs. As such, potassium sparing diuretics
(which TDs are not) do not tend to be given together with RAS-acting drugs to reduce the risk
of hyperkalemia [59]. To ensure that the results are not driven by the differences in TD use, we
conducted a sensitivity analysis in a sample that dropped all observations with use of TDs.
These results (S5 and S6 Tables) show small changes in the magnitudes of some of the esti-
mates, but the not in the statistical significance and are consistent with the main results.
Other robustness checks included varying the definition of user, with thresholds at 180
(S7 and S8 Tables) and 270 (S9 and S10 Tables) days of use, instead of 90. These adjustments
require more adherent use of all the AHTs, including the non-RAS-acting classes in our com-
parison group. These results show that the differences between ACEIs and ARBs, and across
sex, are robust to the definition of user. Differences between RAS and non-RAS drugs for
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white males were no longer statistically different with a more restrictive definition of user
(270 days).
Conclusion
Our findings suggest that the use of certain AHTs could provide benefits in addition to those
ordinarily associated with blood pressure reductions. ARBs may be more protective against
AD than ACEIs, and thus could reduce some of the burden of AD for the afflicted individuals,
their caregivers, and the health system as a whole. The burden of AD is multifaceted and dispa-
rate, and even small delays in AD onset can lead to disproportionately larger reductions in this
large and growing burden. For example, if it were possible to achieve a one year delay in the
onset of AD, this would lead to a reduction in the U.S. population ages 70 and older with AD
in 2050 by 14% and savings of $219 billion in medical and caregiving costs in 2050 [2]. A five-
year delay in AD onset would reduce the U.S. population with AD in 2050 by 41% [2].
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